Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 259Cyclophosphamide 244Specimen Handling 197fludarabine 175Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 122Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82fludarabine phosphate 79Gemcitabine 79Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Azacitidine 57Radiation 56Fluorouracil 56durvalumab 54Radiosurgery 53Temozolomide 48Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Bexarotene × 1 year × Clear all
NCT05296304 2026-02-04

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
20 enrolled
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

National Cancer Centre, Singapore

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡